WO2025149974 - COMBINATION THERAPY WITH AN ANTI-ALPHA4BETA7 ANTIBODY
National phase entry is expected:
Publication Number
WO/2025/149974
Publication Date
17.07.2025
International Application No.
PCT/IB2025/050312
International Filing Date
10.01.2025
Title **
[English]
COMBINATION THERAPY WITH AN ANTI-ALPHA4BETA7 ANTIBODY
[French]
POLYTHÉRAPIE AVEC UN ANTICORPS ANTI-ALPHA4BÊTA7
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
ADSUL, Shashi Damodar
OBERAI, Pooja Chetan
JONES, Stephen
Priority Data
63/619,863
11.01.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3122 | |
| EPO | Filing, Examination, Granting | 23964 | |
| Japan | Filing, Examination, Granting | 3051 | |
| South Korea | Filing, Examination, Granting | 3895 | |
| USA | Filing, Examination, Granting | 9540 |
Total:
43,572
Contact Us
Abstract[English]
The invention provides methods related to combination therapies comprising an anti- alpha4beta7 antibody, e.g., vedolizumab, and a JAK1 inhibitor, e.g., upadacitinib, for treating inflammatory bowel disease, such as Crohn's disease.[French]
L'invention concerne des méthodes associées à des polythérapies contenant un anticorps anti-alpha4bêta7, p. ex., le védolizumab, et un inhibiteur de JAK1, p. ex., l'upadacitinib, permettant de traiter une maladie intestinale inflammatoire telle que la maladie de Crohn.